1293P Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial

B.J. Solomon(Peter MacCallum Cancer Centre), M.E. Cabanillas(The University of Texas MD Anderson Cancer Center), Ashish C. Massey(Albert Einstein College of Medicine), Xi Rao(Indiana University School of Medicine), Anna M. Szpurka(Eli Lilly (United States)), Hyung Jin Won(Eli Lilly (United States)), L.J. Wirth(Massachusetts General Hospital), Jean L. Wright(University of North Carolina at Chapel Hill), S. G. Barker(Eli Lilly (United States)), A.E. Drilon(Memorial Sloan Kettering Cancer Center)
Annals of Oncology
September 1, 2024
Cited by 1


Related Papers